NCT04164979View on ClinicalTrials.gov

Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

February 4, 2020

Primary Completion Date

November 25, 2023

Study Completion Date

May 30, 2026

Conditions
Gastric AdenocarcinomaGastroEsophageal Cancer
Interventions
DRUG

Cabozantinib

Given PO

DRUG

Pembrolizumab

Given IV

Trial Locations (1)

92868

Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange

Sponsors

Collaborators (1)

Exelixis
All Listed Sponsors
collaborator

Exelixis

INDUSTRY

lead

University of California, Irvine

OTHER

NCT04164979 - Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma | Biotech Hunter | Biotech Hunter